(ANSA) - ROME, 07 JAN - There are no substantial differences in terms of efficacy that can lead to one anti Covid vaccine rather than another, both for the general population and for those who face or have faced cancer.
This was highlighted by the vice president Foce (Federation of oncologists, cardiologists and hematologists), and president Aiom (Italian association of medical oncology) Giordano Beretta.
If Foce's indication to vaccinate with absolute priority, like health workers, some cancer patients in particular the most fragile, such as those under active immunosuppressive treatment, which are about 150 thousand, were to be effectively reflected in the vaccination plan "and these patients should enter the first bracket - notes Beretta - as Pfizer and Moderna vaccines are available at the moment, they will do those ".
"The probability of efficacy - he adds - is the same and very high for all vaccines. Some have logistical and organizational problems. They must be kept at very low temperatures, such as Pfizer but also Moderna, and this can create problems from point of view of mass vaccination, which could be much easier with vaccines such as the Astraneneca one in which there is no such limit ".
"There are no data of greater advantage than one over the other - he concludes - of course, having been approved with a certain speed, we cannot be sure of equality between all, but the available data say that there is no difference in terms of terms of effectiveness, I therefore do not see the need for access to one rather than another ".
(HANDLE).
